scientific program - World Allergy Organization

More documents

Recommendations

Info

MONDAY 62 WAO Congress–XVIII ICACI Final Program MONDAY, 8 SEPTEMBER Poster Sessions 15:45 - 17:00 Exhibit Hall C, Vancouver Convention & Exhibition Centre Posters are on display 9:00 – 17:00. Authors are present to discuss their posters 15:45 – 17:00. No CME Credit will be awarded for this activity. Airway Disease P-1-1 Factors of airway hyperresponsiveness in patientswith chronic airflow limitation Choi BW1 , Park IW2 , Kim JY1 1Chung-Ang University Yongsan Hospital, Seoul, Republic of Korea, 2Chung-Ang University Pildong Hospital, Seoul, Republic of Korea P-1-2 Can nasal allergy lead to secretory otitis media? Our experience Passàli D1 , Damiani V1 , Saginario V1 , Bellussi L11ENT Department, University of Siena, Siena, Italy P-1-3 Differences in pulmonary function and allergic tests between COPD patients with wheeze and those without wheeze Sakamoto Y1 , Takei T1 , Ito K1 , Kuboshima M2 , Kuboshima Y2 , Fukushi M2 , Kikuchi S2 , Nishi Y2 , Sakata K2 , Nagata M2 , Kuramitsu K2 1Yugawara Kousei Nenkin Hospital, Yugawara, Kanagawa, Japan, 2Saitama Medical School, Moroyama, Saitama, Japan P-1-4 Cytokine status of patients with chronic bronchitis development caused by secondary immunodeficiency Sepiashvili YR1 , Slavyanskaya TA1 , Chikhladze MV1 1National Institute of Clinical Immunology, Allergology and Asthma, Moscow, Russian Federation P-1-5 Acute bagassosis masquerading respectively as pulmonary infection, tuberculosis and congestive cardiac failure Ishaq IM1 1Al-Junaid Hospital, Nowshera, NWFP, Pakistan P-1-6 Elevated C reactive protein in asthma Condemi JJ1 , Pattanaik D2 1Allergy Asthma Immunology of Rochester PC, Rochester, NY, USA, 2University of Rochester, Rochester, NY, USA P-1-7 Allergic diseases: defending and compensative immune reactions, clinical symptoms and determination of efficient treatment Koryukina IP1 , Mishlanov VJu1 , Sidorov DV2 , Tuev AV1 1 2 Perm State Medical Academy, Perm, Russian Federation, "Ust- Kachka resort”, Ust-Kachka, Perm region, Russian Federation P-1-8 Role of the condensate of exhaled air in the objectification of the degree of gravity of smoking patients with chronic obstructive pulmonary disease Ivashkevich DL1 1Belorushian State Medical University, Minsk, Belarus P-1-9 Clinical features differentiating patients with atopic asthma (AA), nonatopic asthma (NA) and COPD Halasa M1 , Halasa J2 , Machalinski B1 1General Pathology Department, Pomeranian Academy of Medicine, Szczecin, Poland, 2Microbiology and Immunology Department, Pomeranian Academy of Medicine, Szczecin, Poland P-1-10 Immune changes in patients with chronic obstructive bronchitis Samoylova NE1 , Sokurenco SI1 , Ershova OV1 , Karaulov AV1 , Bondarenko NL1 1Sechenov Moscow Medical Academy, Moscow, Russian Federation POSTER SESSIONS P-1-11 Serum levels of oncostatin-M in relation to respiratory syncytial virus infection in wheezy infants Nisli K1 , Önes SÜ1 , Tamay Z1 , Güler N1 1Istanbul University, Istanbul Medical Faculty, Department of Pediatrics, Istanbul, Turkey Asthma: Therapy P-2-1 Effect of suplatast tosilate (IPD), a Th2 cytokine inhibitor, on moderate to severe persistent asthma Nakagawa T1 , Miyamoto T2 1Dept. Int. Med., St. Marianna University Sch. Med., Kawasaki, Kanagawa, Japan, 2Japan Clinical Allergy Institute, Tokyo, Tokyo, Japan P-2-2 Identifying predictors of response to suplatast tosilate among patients with moderate or severe asthma on steroid therapy Nakagawa T1 , Okayama Y2 , Oka T2 1Dept. Int. Med., St. Marianna University Sch. Med., Kawasaki, Kanagawa, Japan, 2Res. Lab. Optimal Medication, Taiho Pharm. Co. Ltd, Tokushima, Tokushima, Japan P-2-3 Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations compared with fixed dosing: a 5-month study in Canada FitzGerald M1 , Boulet LP2 , McIvor A3 , Becker A4 , Sears MR5 , Ernst P6 , Smiljanic-Georgijev N7 , Lee J7 1University of British Columbia, Vancouver, British Columbia, Canada, 2Laval University, Quebec, Quebec, Canada, 3Dalhousie University, Halifax, Nova Scotia, Canada, 4University of Manitoba, Winnipeg, Manitoba, Canada, 5McMaster University, Hamilton, Ontario, Canada, 6McGill University, Montreal, Quebec, Canada, 7AstraZeneca Canada Inc., Mississauga, Canada P-2-4 Assessment of infectious nonatopic asthma and COPD patients’ treatment with autovaccine: double-blind placebocontrolled trial Halasa M1 , Halasa J2 1General Pathology Department, Pomeranian Academy of Medicine, Szczecin, Poland, 2Microbiology and Immunology Department, Pomeranian Academy of Medicine, Szczecin, Poland P-2-5 Budesonide/formoterol adjustable maintenance dosing effectively improves asthma symptom severity: a multicentre Canadian study Sears MR1 , McIvor A2 , Becker A3 , FitzGerald M4 , Boulet LP5 , Ernst P6 , Smiljanic-Georgijev N7 , Lee J7 1 2 McMaster University, Hamilton, Ontario, Canada, Dalhousie University, Halifax, Nova Scotia, Canada, 3University of Manitoba, Winnipeg, Manitoba, Canada, 4University of British Columbia, Vancouver, British Columbia, Canada, 5Laval University, Quebec, Quebec, Canada, 6McGill University, Montreal, Quebec, Canada, 7AstraZeneca Canada Inc., Mississauga, Canada P-2-6 Study of asthmatic children with treatment of Ketotifen Douglas Campbell MDC1 110 de Octobre Pediatric - Obstetric Hospital, Havana, Havana City, Cuba P-2-7 Ipratropium bromide plus nebulized β-2 agonist for the treatment of hospitalized children with acute asthma attack Özdemir M 1 , Akçakaya N 1 , Camcioglu Y 1 , Çokugras H 1 1 IU. Cerrahpasa Medical Faculty, Dept. of Pediatrics, Allergy Division, Istanbul, Turkey
WAO Congress–XVIII ICACI Final Program MONDAY, 8 SEPTEMBER - continued POSTER SESSIONS P-2-8 Nedocromil sodium in the treatment of moderate and severe asthma Zdraveska MM1 , Dimitrioevska DT1 , Gjorcev AS1 , Todevski D1 , Dokic D1 1Pulmology and Allergy Clinic, Skopje, Macedonia P-2-9 Onset of action and duration of bronchodilator effect of nebulized formoterol solution Rosario NA1 , Mascarenhas E1 , Riedi CA1 , Kamoi T1 1Federal University of Parana, Curitiba, Parana, Brazil P-2-10 The effects of montelukast on pulmonary function and bronchial hyperresponsiveness in asthmatic children Visitsunthorn N1 , Chirdjirapong V1 , Santadusit S1 , Jirapongsananuruk O1 , Kolmontri C2 , Vichyanond P1 1Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, Thailand, 2Siriraj Hospital, Mahidol University, Bangkok, Thailand P-2-11 Patients suffering with asthma exacerbations treatment with high doses of inhaled corticosteroids and their quality of life Gogunskaya IV1 , Yashina LA2 , Gorovenko NG3 1 2 City Hospital, Melitopol, Zaporizhzhya, Ukraine, Institute of Ftisiopulmonology, Kiev, Ukraine, 3Postgraduate Medical Academy, Kiev, Ukraine P-2-12 Effect of cysteinyl leukotriene receptor antagonist on airway wall remodeling Toda M1 , Cheng G1 , Masuda H1 , Honda K1 , Eda F1 , Aoki Y1 , Fukuda T1 1Dokkyo University School of Medicine, Mibu, Tochigi, Japan P-2-13 Poor adherence to NAEPP2 guidelines of patients with mild to moderate asthma Wineinger JC1 , Naguwa S1 , Teuber S1 , Ziboh V1 , Gershwin ME1 1UC Davis School of Medicine, Davis, CA, USA P-2-14 The effectiveness of pranlukast hydrate, a leukotriene receptor antagonist, in the treatment of childhood bronchial asthma Ikeda M1 , Araki T1 , Takahashi A1 , Kanbe T1 , Takemoto Y1 , Kitamura T2 1National Fukuyama Hospital, Fukuyama, Hiroshima, Japan, 2Nihonkokan Fukuyama Hospital, Fukuyama, Hiroshima, Japan P-2-15 Efficacy of local nasal immunotherapy for Dp2-induced airway inflammation in mice: using Dp2 peptide and fungal immunomodulatory peptide Liu YH1 , Kao MC2 , Lai YL2 , Tsai JJ1 1Section of Allergy and Immunology, Cathay General Hospital- Taipei, Taipei, Taiwan, 2Graduate Institute of Physiology, College of Medicine, NTU, Taipei, Taiwan P-2-16 Improvement of asthma control with the use of combined medicine salmeterol + fluticasone (two-in-one) Feschenko YI1 , Yashyna LA1 , Polyanska MA1 , Gymenuk GL1 , Sidun GV1 , Klochko LT1 1Institute of Phthisiology and Pulmonology, Kiev, Ukraine P-2-17 Effectiveness of HFA beclomethasone dipropionate vs CFC beclomethasone dipropionate in moderately asthmatic patients Feschenko YI1 , Yashyna LA1 , Polyanska MA1 , Tumanov AN1 , Djavad IV1 , Chepel JA1 1Institute of Phthisiology and Pulmonology, Kiev, Ukraine 63 P-2-18 Is well-controlled asthma weeks a useful measure? Fewer exacerbations in patients treated with budesonide/ formoterol than salmeterol/fluticasone Aalbers R1 , Backer V2 , Kava TTK3 , Welte T4 , Omenaas ER5 , Bergqvist PBF6 , Sandström T7 1Department of Pulmonology, Martini Hospital, Groningen, Netherlands, 2Respiratory Unit, Dept. of Internal Medicine, Bispebjerg Hospital, Copenhagen, Denmark, 3Lääkärikeskus ITE Oy Siltakatu 10 A 3 krs, Joensuu, Finland, 4Dept. of Pneumology & Intensive Care Medicine, University of Magdeburg, Magdeburg, Germany, 5Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway, 6AstraZeneca R&D Lund, Lund, Sweden, 7Dept. of Respiratory Medicine & Allergy, University Hospital, Umea, Sweden P-2-19 Improvements in FEV are greater with budesonide/ 1 formoterol than with salmeterol/fluticasone Aalbers R1 , Backer V2 , Kava TTK3 , Welte T4 , Omenaas ER5 , Bergqvist PBF6 , Sandström T7 1Department of Pulmonology, Martini Hospital, Groningen, Netherlands, 2Respiratory Unit, Dept. of Internal Medicine, Bispebjerg Hospital, Copenhagen, Denmark, 3Lääkärikeskus ITE Oy Siltakatu 10 A 3 krs, Joensuu, Finland, 4Dept. of Pneumology & Intensive Care Medicine, University of Magdeburg, Magdeburg, Germany, 5Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway, 6AstraZeneca R&D Lund, Lund, Sweden, 7Dept. of Respiratory Medicine & Allergy, University Hospital, Umea, Sweden P-2-20 Adjustable dosing with budesonide/formoterol reduces the rate of asthma exacerbations compared with fixed dosing salmeterol/fluticasone Aalbers R1 , Backer V2 , Kava TTK3 , Welte T4 , Omenaas ER5 , Bergqvist PBF6 , Sandström T7 1Department of Pulmonology, Martini Hospital, Groningen, Netherlands, 2Respiratory Unit, Dept. of Internal Medicine, Bispebjerg Hospital, Copenhagen, Denmark, 3Lääkärikeskus ITE Oy Siltakatu 10 A 3 krs, Joensuu, Finland, 4Dept. of Pneumology & Intensive Care Medicine, University of Magdeburg, Magdeburg, Germany, 5Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway, 6AstraZeneca R&D Lund, Lund, Sweden, 7Dept. of Respiratory Medicine & Allergy, University Hospital, Umea, Sweden P-2-21 Influences of inhaled fluticasone propionate (FP) and pranlukast hydrate on asthmatic children in National Ootake Hospital night clinic Okahata H1 1National Ootake Hospital, Ootake, Hiroshima, Japan P-2-22 Oral delivery of recombinant Der p 2 allergen can alleviate airway inflammation in murine model of asthma Ho H1 , Jeng ST2 , Chiang BL1 1Graduate Institute of Immunology, College of Medicine, NTU, Taipei, Taiwan, 2Department of Botany, College of National Taiwan University, Taipei, Taiwan P-2-23 Further data about the treatment of allergic asthma with acupuncture Cucci M1 , Garofano G1 , Geroldi GF1 , Pirino A2 1Italian Advanced Institute of Acupuncture, Milano, Italy, 2Department of Biomedical Sciences, University of Sassari, Sassari, Italy P-2-24 Importance of early intervention with salmeterol plus inhaled corticosteroids in the treatment of asthma Suzuki N 1 , Fueta M 1 , To M 1 , Yamada H 1 , Ogawa C 1 , Sano Y 1 1 Dept. Allergy & Resp. Med., Doai Memorial Hospital, Tokyo, Japan MONDAY
Page 1:
FINAL PROGRAM World Allergy Organiz
Page 4 and 5:
2 WAO Congress-XVIII ICACI Final Pr
Page 6 and 7:
4 World Allergy Organization (WAO)-
Page 8 and 9:
6 WAO Congress-XVIII ICACI Final Pr
Page 10 and 11:
8 sneezing runny nose itchy nose it
Page 12 and 13:
10 PRECAUTIONS (continued) ADVERSE
Page 14 and 15: 12 WAO Congress-XVIII ICACI Final P
Page 23 and 24: WAO Congress-XVIII ICACI Final Prog
Page 25 and 26: Whistler alpine resort WAO Congress
Page 29 and 30: XXIII EAACI Congress 12-16 June 200
Page 31 and 32: 7:00 8:00 9:00 10:00 11:00 12:00 13
Page 49 and 50: WEDNESDAY WEDNESDAY SEPTEMBER SEPTE
Page 51 and 52: www.annualmeeting.aaaai.org Visit w
Page 59 and 60: Presenting authors indicated in bol
Page 61 and 62: FRIDAY, 12 SEPTEMBER WAO Congress-X
Page 63: Imagine research targeting IgE, a k
Page 98 and 99: 96 PLAN TO ATTEND! SOYEZ DES NÔTRE
Page 100 and 101: 98 Dolovich, Myrna Canada BR86 Dubo
Page 102 and 103: 100 Schnuch, Axel Germany BR88 Scho
Page 104 and 105: 102 201 ACII - Journal of the World
Page 106 and 107: 104 WAO Congress-XVIII ICACI Final
Page 114 and 115:
112 WAO Congress-XVIII ICACI Final
Page 116 and 117:
114 Crowne Plaza Hotel Georgia 801
Page 118 and 119:
Page 120 and 121:
118 (salmeterol xinafoate/fluticaso
Page 122 and 123:
COPD, the most commonly reported dr
Page 124 and 125:
Page 126 and 127:
124 Seaplane landing at sunset Gran
Page 128:
DS2 - Dinner Symposium Monday, 8 Se
show all

scientific program - World Allergy Organization

Create successful ePaper yourself

Delete template?

Save as template?